Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
According to researchers from the Karolinska Institutet, patients with Crohn's disease and IBD have an elevated risk of developing lymphoma, and this risk has grown over the past few years.
Read Full NewsPublished phase 3 data in JAMA Neurology highlighted tofersen's potential to slow ALS progression and improve survival, marking a breakthrough in SOD1-ALS treatment.
Adding CBT to Quetiapine Significantly Reduces Suicide Risk in Mood Disorders
Iron Polymaltose Complex Outperforms Liposomal Iron in Pediatric CKD Anemia
FDA Requests Removal of Suicidal Ideation and Behavior Warning From GLP-1 RA Therapies
Melanoma Surgery Delay After 4 Weeks Post-Diagnosis Decreases Survival Rates
1.
Mental health risk persists years after cancer diagnosis
2.
Using MRD Status to Deescalate Multiple Myeloma Therapy
3.
Males with early-onset colorectal cancer are at risk, according to a study.
4.
Research finds low uptake of supportive care at the end-of-life for patients with advanced cancer
5.
According to new studies, some cancer patients can safely forego radiation therapy.
1.
Neuroendocrine Tumors: Mechanisms of Mortality, Associated Conditions
2.
Introduction To Immune Thrombocytopenic Purpura
3.
Studying Lactic Acid in Pediatric Tumor Microenvironments: Experimental Approaches Explored
4.
Prognostic Role of PLAU in Pan-Cancer and Neutrophil Infiltration in Bladder Cancer
5.
The Benefits of Understanding Haptoglobin High: What You Need to Know
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
3.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
4.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge